NDVLC Statement on Authorized Generic Insulin

March 8, 2019

Lilly’s plan to release an authorized generic for Humalog is an important step toward more affordable insulin in the United States. It will help people currently struggling with high out-of-pocket costs for a lifesaving medicine and accelerate the growing shift away from a rebate system that disproportionately harms people with diabetes or other chronic diseases.

We recognize the problems in our health care system are too complex for one company or industry to solve. All health care system stakeholders have roles in a comprehensive and lasting solution to rising costs.

NDVLC will continue working with advocacy partners, manufacturers, employers and other health plan sponsors, insurers, pharmacy benefit managers, health care providers and policymakers until every person affected by diabetes has effective, affordable health care and a discrimination-free environment.

* * *

The National Diabetes Volunteer Leadership Council (NDVLC) acts on emerging and evolving issues that impact people with diabetes by convening, collaborating, and communicating with the diabetes ecosystem to drive results. NDVLC is comprised of individuals who combine their passion for advocacy with decades of diabetes experience and leadership to advance patients-first policies at the local, state and national levels. Our members – all former leaders of national diabetes organizations – engage policymakers, and public and private sector influencers to call attention to the diabetes epidemic and provide a voice for 30 million Americans living with the disease. For more information, go to ndvlc.org.